次世代エネルギー産業・グリーン経済の国際リサーチ情報サイト

ニキビ治療薬の世界市場:2025年に至るニキビタイプ別、薬剤分類別予測

Acne Drugs Market Size, Share & Trends Analysis Report By Type, By Therapeutic Class (Retinoid, Antibiotic, Combination), By Mode of Administration (Injectable, Topical, Oral), And Segment Forecasts, 2018 - 2025

出版元:Grand View Research(米国)LinkIcon出版元について
発行年:2018年8月
定価 Single User License(1名様ライセンス)US$5,950(米国ドル)/Multi User License(5名様)$7,950 /Enterprise License $9,950
ご予算に応じた各種ご提案も承ります。詳細はお問い合わせください。
ご請求は円換算(お見積り日TTSレート)となります。
納品形態:PDF by Email (※PDFコンテンツ保護/DRM設定あり)
当調査レポートは英文 83ページになります。
商品コード:GRAN045

お問い合わせ、お見積りのリクエストは下のボタンをクリックしてご入力ください。



【レポート紹介】
ニキビ治療薬の世界市場規模は、2025年に59億ドルにまで拡大すると予測されます。
当レポートでは、2025年に至るニキビ治療薬市場の世界市場予測(市場規模US$)、タイプ別市場(面皰、炎症性、嚢胞性、手術後/創傷)、薬剤分類別市場(レチノイド、抗生物質、ホルモン剤、配合剤)、投与経路別市場(局所、注射、経口)、主要7ヶ国別市場など、各種の予測データに基づき市場を展望しています。また市場動向、競合状況、主要企業プロフィールなどの分析も交えて、概略以下の構成でお届けいたします。

【レポート構成概要】pic_GRAN_cover-new-3.png
◆ ニキビ治療薬の世界市場予測2017-2025年
・市場規模(US$)

◆ タイプ別、市場-2025年
・面皰
・炎症性
・嚢胞性
・手術後/創傷
※(市場規模US$)

◆ 薬剤分類別、市場-2025年
・レチノイド
・抗生物質
・ホルモン剤
・配合剤
※(市場規模US$)

◆ 投与経路別、市場-2025年
・局所
・注射
・経口
※(市場規模US$)

◆ 主要7ヶ国、国別市場-2022年
・米国、英国、ドイツ、スペイン
・イタリア、フランス、日本
・その他地域(Rest of the World)
※ 国別に治療薬別、投与経路別の細分化データ掲載、詳細は目次参照
※ (市場規模US$)

◆市場分析
・市場ドライバー/障壁
・業界構造分析(ファイブフォース分析)
・PESTEL分析
・競合状況

◆ 研究開発動向
パイプライン状況
・開発中の薬
主要研究開発動向
・モノクローナル抗体
・ステアロイル-CoAデサチュラーゼ
・メラノコルチン受容体アンタゴニスト
後期開発パイプライン
革新的新薬概要
・Seysara
・CJM112
・FMX-101
・TWIN (S6G5T-1, S6G5T-3)

◆ ニキビ治療薬の主要企業プロフィール動向
・ALLERGAN
・BAYER
・GALDERMA S.A.
・STIEFEL
・VALEANT

(全83貢)
【レポート詳細目次、データ項目一覧は当ページ下を参照ください】

英文詳細目次(table of contents)

【原文詳細目次】

Acne Drugs Market Size, Share & Trends Analysis Report By Type, By Therapeutic Class (Retinoid, Antibiotic, Combination), By Mode of Administration (Injectable, Topical, Oral), And Segment Forecasts, 2018 - 2025

Table of Contents

Chapter 1 Methodology and Scope

1.1 Research Methodology
1.2 Research Scope and Assumptions
1.3 List to Data Sources
1.4 List of Abbreviations

Chapter 2 Executive Summary
Chapter 3 Disease Primer and Epidemiology

3.1 Disease Primer
3.1.1 Forms
3.1.2 Causative Factors and Triggers
3.1.3 Degree of Severity
3.2 Epidemiology
3.3 Current Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)
3.4 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, EU5)

Chapter 4 Global Acne Drugs Market Overview

4.1 Introduction and Market Overview
4.1.1 Segmentation, by type
4.1.1.1 Comedonal
4.1.1.2 Inflammatory
4.1.1.3 Cystic
4.1.1.4 Post-Surgical/wound
4.1.2 Segmentation, by therapeutic class
4.1.2.1 Retinoid
4.1.2.2 Antibiotic
4.1.2.3 Hormonal Agent
4.1.2.4 Combination
4.1.2.5 Others
4.1.3 Segmentation, by mode of administration
4.1.3.1 Topical
4.1.3.2 Oral
4.1.3.3 Injectable
4.1.4 Segmentation, by major market
4.1.4.1 U.S.
4.1.4.2 EU5
4.1.4.3 Japan
4.1.5 Market size and forecast
4.1.6 Sales performance
4.1.7 Market dynamics among leading brands
4.2 Patent Expiry Schedule
4.3 Drivers and Challenges
4.4 Deals Landscape (2013-2018)
4.5 Pricing and Reimbursement
4.6 Emerging Markets
4.6.1 India
4.6.2 South Korea
4.6.3 Brazil
4.6.4 Mexico
4.7 SWOT Analysis

Chapter 5 Acne Drugs Market: Pipeline Intelligence

5.1 Pipeline Landscape
5.1.1 Drugs under Development
5.2 Key R&D Trends
5.2.1 Monoclonal Antibodies
5.2.2 Stearoyl-CoA desaturase
5.2.3 Melanocortin Receptor Antagonist
5.3 Late-Stage Pipeline
5.4 Profile of Disruptive Drugs
5.4.1 Seysara
5.4.2 CJM112
5.4.3 FMX-101
5.4.4 TWIN (S6G5T-1, S6G5T-3)

Chapter 6 Company Profiles

6.1 Allergan
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales
6.1.4 Company - key news flow
6.1.5 Pipeline View
6.1.6 Pipeline Forecast
6.1.7 Catalysts and Event Calendar
6.1.8 SWOT Analysis
6.2 Bayer
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales
6.2.4 Company - key news flow
6.2.5 SWOT Analysis
6.3 Galderma S.A.
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales
6.3.4 Company - key news flow
6.3.5 Pipeline View
6.3.6 Pipeline Forecast
6.3.7 SWOT Analysis
6.4 Stiefel
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales
6.4.4 Company - key news flow
6.4.5 SWOT Analysis
6.5 Valeant
6.5.1 Company Overview
6.5.2 Current Product Portfolio
6.5.3 Product Forecast Sales
6.5.4 Company - key news flow
6.5.5 Pipeline View
6.5.6 Pipeline Forecast
6.5.7 Catalysts and Event Calendar
6.5.8 SWOT Analysis

Chapter 7 Market Outlook

7.1 Winners and Losers
7.2 Emerging Companies
7.3 What the Future Holds

List of Tables

Table 1 List of Abbreviation
Table 2 Acne Prevalence and Incidence Rates - 2017 (in %)
Table 3 Forecast Acne Prevalence and Incidence Rates, 2017A - 2025E (in %)
Table 4 Acne Type and Treatment
Table 5 Acne Drugs Market Size and Forecast (in USD Million)
Table 6 Geographic Sales Performance, by Seven Major Markets (in USD Million)
Table 7 Acne Drugs Market, by Type (in USD Million)
Table 8 Acne Drugs Market, by Therapeutic Class (in USD Million)
Table 9 Acne Drugs Market, by Mode of Administration (in USD Million)
Table 10 Acne Drugs - U.S. Patent Expiry Schedule
Table 11 Acne Deals Landscape (2013-2018)
Table 12 Acne Product Pricing
Table 13 Acne Drugs in Development
Table 14 Late-Stage Acne Pipeline
Table 15 Pipeline Forecast - Global Acne Drugs
Table 16 Profile of Disruptive Drug: Seysara
Table 17 Profile of Disruptive Drug: CJM112
Table 18 Profile of Disruptive Drug: FMX-101
Table 19 Profile of Disruptive Drug: TWIN (S6G5T-1, S6G5T-3)
Table 20 Product Portfolio: Allergan
Table 21 Allergan Product Forecast Sales 2017A - 2025E (in USD Million)
Table 22 Allergan Pipeline View
Table 23 Allergan Catalysts and Event Calendar
Table 24 Product Portfolio: Diane-35
Table 25 Diane Product Forecast Sales 2017A - 2025E (in USD Million)
Table 26 Product Portfolio: Galderma
Table 27 Galderma Product Forecast Sales 2017A - 2025E (in USD Million)
Table 28 Galderma Pipeline View
Table 29 Product Portfolio: Stiefel
Table 30 Duac Product Forecast Sales 2017A - 2025E (in USD Million)
Table 31 Product Portfolio: Valeant
Table 32 Valeant Product Forecast Sales 2017A - 2025E (in USD Million)
Table 33 Valeant Pipeline View
Table 34 Valeant Catalysts and Event Calendar

List of Figures

Fig.1 Acne - Main Causative Factors
Fig.2 Acne - Degree of Severity
Fig.3 Current Prevalence Across Seven Major Markets - 2017
Fig.4 Current Incidence Across Seven Major Markets - 2017
Fig.5 Market Segmentation and Scope
Fig.6 Geographic Sales Performance by Seven Major Markets 2017
Fig.7 Acne Drugs Market, by Type (2017)
Fig.8 Acne Drugs Market, by Therapeutic Class, 2017A - 2025E (in USD Million)
Fig.9 Acne Drugs Market Share, by Therapeutic Class (2017)
Fig.10 Acne Sales Trend, by Mode of Administration 2017 (in USD Million)
Fig.11 U.S. Acne Drugs Market, by Type (in USD Million)
Fig.12 U.S. Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.13 U.S. Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.14 U.K. Acne Drugs Market, by Type (in USD Million)
Fig.15 U.K. Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.16 U.K. Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.17 Germany Acne Drugs Market, by Type (in USD Million)
Fig.18 Germany Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.19 Germany Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.20 Spain Acne Drugs Market, by Type (in USD Million)
Fig.21 Spain Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.22 Spain Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.23 France Acne Drugs Market, by Type (in USD Million)
Fig.24 France Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.25 France Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.26 Italy Acne Drugs Market, by Type (in USD Million)
Fig.27 Italy Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.28 Italy Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.29 Japan Acne Drugs Market, by Type (in USD Million)
Fig.30 Japan Acne Drugs Market, by Therapeutic Class (in USD Million)
Fig.31 Japan Acne Drugs Market, by Mode of Administration (in USD Million)
Fig.32 Acne Drugs Market Share Distribution, by Company (2017A - 2025E)
Fig.33 Market Trends & Outlook
Fig.34 Market Driver Relevance Analysis (Current & Future Impact)
Fig.35 Market Restraint Relevance Analysis (Current & Future Impact)
Fig.36 SWOT Analysis (Acne Drugs Market)
Fig.37 Pipeline Assets, by Phase
Fig.38 SWOT Analysis (Allergan)
Fig.39 SWOT Analysis (Bayer)
Fig.40 SWOT Analysis (Galderma)
Fig.41 SWOT Analysis (Stiefel)
Fig.42 SWOT Analysis (Valeant)

プレスリリース

プレスリリース

Memo.png当レポートのプレスリリースは発行されておりません。

資料検索

お探しの資料・レポートをキーワードで検索ください。

当サイト内の検索結果が表示されます。調査レポートは英文目次を掲載しているため、英語検索も有効です。
(ブラウザのスクリプトを有効にしないとサーチエンジンが表示されません)

お問い合わせ

2714110_0.jpg
レポートをお探しいたします。
当サイトに掲載されているレポート以外にも幅広くご提案可能です。レポートの内容に関するご質問、ご確認にも回答いたします。お気軽にお問い合わせください。